Introduction
============

Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world and a leading cause of cancer death.[@b1-cmar-10-2231] Transcatheter intra-arterial therapies, including transcatheter arterial chemoembolization (TACE) and transcatheter arterial infusion chemotherapy (TAI), are endorsed in practice guidelines as major treatment options for patients with unresectable HCC.[@b2-cmar-10-2231]--[@b6-cmar-10-2231] However, it is often difficult to exactly predict the prognosis of HCC patients treated with transcatheter intra-arterial therapies in clinical practice, because outcomes are affected by various factors, including the etiology of underlying liver disease; hepatic reserve function; tumor-specific factors, such as number, diameter, and distribution in the liver; and the efficacy of treatment.[@b7-cmar-10-2231]--[@b10-cmar-10-2231] Furthermore, a close association between sarcopenia and clinical outcomes of HCC has been shown in recent studies, and, thus, body composition changes related to skeletal muscle loss may also affect prognosis.[@b11-cmar-10-2231],[@b12-cmar-10-2231] It is important to identify all contributors to the prognosis for precise prediction.

Body mass index (BMI) is a widely used anthropometric index to assess the degree of obesity and is associated with clinical outcomes of malignancies including HCC.[@b13-cmar-10-2231] In addition, recent studies have revealed that quantification of several body compositions, such as skeletal muscle mass and visceral and subcutaneous adipose tissue (VAT and SAT, respectively) volumes, is also useful to predict the prognosis of HCC patients treated with various methods, including surgical resection, radiofrequency ablation, and tyrosine kinase inhibitors.[@b14-cmar-10-2231]--[@b17-cmar-10-2231] However, there has been no study that specifically focused on the association between body composition and outcomes of HCC patients treated with transcatheter intra-arterial therapies.

In this study, we retrospectively measured the area of skeletal muscle, VAT, and SAT using cross-sectional computed tomography (CT) images in HCC patients treated with trans-catheter intra-arterial therapies. We statistically analyzed the association between these body compositions and outcomes and evaluated the prognostic value of the body compositions.

Patients and methods
====================

Patients
--------

We retrospectively analyzed consecutive HCC patients who underwent transcatheter intra-arterial therapies as initial treatment at Niigata University Medical and Dental Hospital between January 2005 and December 2015. The diagnosis of HCC was confirmed on the basis of typical enhancement patterns on dynamic CT or dynamic magnetic resonance imaging, i.e., contrast enhancement in the arterial phase and subsequent washout in the equilibrium phase.[@b18-cmar-10-2231] When the typical enhancement patterns of HCC were not depicted, the diagnosis of HCC depended on histopathological analyses by tumor biopsy. Exclusion criteria were as follows: 1) presence of massive ascites or subcutaneous edema; 2) undergoing initial treatment other than TACE or TAI; and 3) achievement of complete response (CR) by additional radical treatment with surgical resection or local ablation therapies such as radiofrequency ablation following transcatheter intra-arterial therapies.

This retrospective study was approved by the ethics committee of Niigata University School of Medicine and carried out in accordance with the 1975 Helsinki Declaration (approval number 2442). Because of the anonymous nature of the data, the requirement for additional informed consent to participate in this study was waived.

Treatment procedure
-------------------

TACE and/or TAI were performed according to the clinical practice guidelines for HCC of the Japan Society of Hepatology.[@b6-cmar-10-2231] Briefly, TACE or TAI is recommended for patients with multiple tumors and liver damage of Child--Pugh class A or B. The TAI procedure consists of injecting IA-Call^®^ (cisplatin) (Nippon Kayaku, Tokyo, Japan), Miripla^®^ (miriplatin) (Dainippon Sumitomo Pharma, Osaka, Japan), or an emulsion of Farmorubicin^®^ (epirubicin) (Pfizer Inc., New York, NY, USA) in lipiodol into hepatic arteries including tumor nourishing arteries. TACE includes subsequent embolization of the feeding arteries with Gelpart^®^ (gelatin sponge particles) (Nihonkayaku, Tokyo, Japan) after TAI. TAI, which was devoid of embolization, was implemented when multiple tumors were extensively distributed in bilateral lobes of the liver, the arterial anatomy precluded a super selective injection, or significant arteriovenous fistulas or tumor thrombi in the main trunk of portal vein existed.

Body composition quantification
-------------------------------

The body composition variables were quantified by the acquisition of a CT scan slice image at the third lumbar vertebra (L3) level undertaken prior to treatment for the purpose of the clinical workup for HCC. The skeletal muscle area was measured using sliceOmatic software (version 5.0; Tomovision, Montreal, QC, Canada; [Figure 1A](#f1-cmar-10-2231){ref-type="fig"}), and the adipose tissue area was determined using Ziostation2 (version 2.1; Ziosoft, Tokyo, Japan; [Figure 1B](#f1-cmar-10-2231){ref-type="fig"}). As previously described, thresholds of tissue Hounsfield units (HU) for delineation of the regions were adopted as follows: −29 to +150 HU for skeletal muscle, −150 to −50 HU for VAT, and −190 to −30 HU for SAT.[@b19-cmar-10-2231],[@b20-cmar-10-2231] These cross-sectional areas (cm^2^) were normalized by the height squared (m^2^) to determine the skeletal muscle index (SMI), VAT index (VATI), and SAT index (SATI). The visceral to subcutaneous adipose tissue area ratio (VSR) was also calculated. The cutoff values for the classification of SMI into low-SMI or high-SMI groups were defined as SMI\<42 cm^2^/m^2^ for men and \<38 cm^2^/m^2^ for women according to the Japanese Society of Hepatology guideline for sarcopenia in liver disease.[@b21-cmar-10-2231] The cutoff values of the VATI, SATI, and VSR were set for each sex using optimal stratification to find the most significant *p*-value by means of a log-rank test as previously described.[@b22-cmar-10-2231],[@b23-cmar-10-2231]

Clinical data
-------------

The following clinical data were retrospectively collected from medical records and used for analysis: age; sex; BMI; hepatitis virus infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), or non-B non-C (NBNC); serum alanine transaminase (ALT) level; serum total bilirubin level; serum albumin level; platelet count; Child--Pugh classification; serum alpha-fetoprotein (AFP) level; tumor node metastasis (TNM) stage;[@b24-cmar-10-2231] maximal tumor size; number of tumors classified into solitary or multiple; branched-chain amino acid (BCAA) supplementation; and treatment response of transcatheter intra-arterial therapies. The treatment response was assessed according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST), and classified as follows: CR, partial response (PR), stable disease (SD), and progressive disease (PD).[@b25-cmar-10-2231]

Overall survival (OS) was calculated based on the days between the date of CT examination prior to treatment and the date of death or December 2015 for surviving patients.

Statistical analyses
--------------------

Continuous variables were expressed as median (interquartile range), and categorical variables were expressed as numbers of patients. The Mann--Whitney *U*-test was used to compare differences in median values. Either Fisher's exact test or the chi-squared test was used to compare differences in categorical variables between groups. The correlations between each body composition index and BMI were analyzed using Spear-man's correlation analysis by sex. OS rates were calculated using the Kaplan--Meier method and compared between groups using a log-rank test. Univariate and multivariate analyses with the Cox proportional hazards model were used to analyze prognostic variables for OS, expressed as HR and 95% CI. All variables were dichotomized, and significant variables in univariate analysis were included in multivariate models. All statistical analyses were conducted using SPSS Statistics version 21 (IBM Corporation, Armonk, NY, USA). All tests of significance were two-sided and *p*\<0.05 was considered statistically significant.

Results
=======

Baseline demographic and clinical characteristics
-------------------------------------------------

Baseline demographic and clinical characteristics of the patients are shown in [Table 1](#t1-cmar-10-2231){ref-type="table"}. A total of 100 patients, including 69 male and 31 female patients, were enrolled in this study. HCC was diagnosed according to histopathological findings in only 4 patients and imaging features in the other 96 patients. Sixty-five patients died during the median observation period of 746 days. The median age of all patients was 71 years, and female patients were significantly older than male patients in the cohort. The SMI and VSR were significantly higher in male than in female patients, whereas the BMI, VATI, and SATI did not significantly differ between men and women. Seventy-two patients were classified into Child--Pugh class A, 28 into class B, and 0 into class C. Fifty-nine patients had advanced HCC which was classified into TNM stage III and IV. Fifty-three patients were treated with the combination of TACE and TAI, and the treatment response of transcatheter intra-arterial therapies was PD in more than half of patients. No difference was observed in TNM stages and treatment response between men and women.

Correlation analyses of body composition indexes and BMI
--------------------------------------------------------

The correlations between each body composition index and BMI were analyzed ([Table 2](#t2-cmar-10-2231){ref-type="table"}). In men, the BMI was significantly correlated with the SMI, VATI, and SATI, but not with the VSR. The SATI showed a significantly negative correlation with the VSR. In contrast, in women there was no significant correlation between the BMI and the VSR or SMI. The correlation between the SATI and the VSR was also not significant in women.

Survival analysis
-----------------

Sex-specific cutoff values for the VATI, SATI, and VSR determined by optimal stratification were as follows: VATI\<44.0 cm^2^/m^2^ for men and \<35.0 cm^2^/m^2^ for women, SATI\<40.0 cm^2^/m^2^ for men and \<30.0 cm^2^/m^2^ for women, and VSR\<1.08 for men and \<0.86 for women. The patients were classified by the cutoff values into low- or high-index groups for each body composition ([Table 3](#t3-cmar-10-2231){ref-type="table"}) and incorporated into the survival analysis.

The results of univariate and multivariate analyses of the Cox proportional hazards model are shown in [Table 4](#t4-cmar-10-2231){ref-type="table"}. Of the body composition indexes, only the SATI was significantly associated with OS in univariate analysis. In addition to the SATI, the serum albumin level, Child--Pugh classification, serum AFP level, TNM stage, maximal tumor size, and mRECIST assessment were also statistically significant predictors for OS in univariate analysis. Of these variables, the SATI (low- vs. high-SATI; HR, 2.065; 95% CI, 1.187--3.593; *p*=0.010), serum albumin level (\<3.5 vs. ≥3.5 g/dL; HR, 2.007; 95% CI, 1.037--3.886; *p*=0.039), serum AFP level (\<20 vs. ≥20 ng/mL; HR, 0.311; 95% CI, 0.179--0.540; *p*\<0.001), and mRECIST assessment (CR+PR+SD vs. PD; HR, 0.392; 95% CI, 0.221--0.696; *p*=0.001) were indicated as independent prognostic factors for OS in multivariate analysis.

Kaplan--Meier survival curves of the patients stratified by BMI and body composition indexes are shown in [Figure 2](#f2-cmar-10-2231){ref-type="fig"}. The log-rank test showed a significant difference in OS stratified only by the SATI (*p*=0.012; [Figure 2D](#f2-cmar-10-2231){ref-type="fig"}), but not by BMI (*p*=0.126; [Figure 2A](#f2-cmar-10-2231){ref-type="fig"}), SMI (*p*=0.701; [Figure 2B](#f2-cmar-10-2231){ref-type="fig"}), and VATI (*p*=0.566; [Figure 2C](#f2-cmar-10-2231){ref-type="fig"}). Although not statistically significant, the OS of the high-VSR group tended to be lower than that of the low-VSR group (*p*=0.067; [Figure 2E](#f2-cmar-10-2231){ref-type="fig"}).

Cross-sectional areas of SAT and VAT measured on CT images in typical cases with high and low SATI are demonstrated in [Figure 3](#f3-cmar-10-2231){ref-type="fig"}. The CT image of patient number 1 with high SATI is shown in [Figure 3A](#f3-cmar-10-2231){ref-type="fig"}. The patient was a 68-year-old man and had an HBV infection, TNM stage III, Child--Pugh class B, SATI of 59.5, and VATI of 56.0. The patient was alive for 1800 days at the observation end time. Patient number 2 was a 73-year-old man with low SATI ([Figure 3B](#f3-cmar-10-2231){ref-type="fig"}). The patient had an HCV infection, TNM stage II, Child--Pugh class A, SATI of 19.5, and VATI of 57.3. The patient died at 751 days.

Comparison of demographic and clinical characteristics between low- and high-SATI groups
----------------------------------------------------------------------------------------

The comparison of baseline demographic and clinical characteristics between patients in the low- and high-SATI groups is shown in [Table 5](#t5-cmar-10-2231){ref-type="table"}. The low-SATI group consisted of 38 men and 7 women, which was a significantly lower proportion of women than in the high-SATI group. The BMI, SMI, and VATI were significantly higher in the high-SATI group; however, the VSR was not. Regarding etiology, NBNC were also significantly more frequent in the high-SATI group. No other variables, including laboratory data, tumor-specific factors, or course of treatment, differed significantly between the two groups.

Discussion
==========

In this study, we retrospectively quantified the volume of skeletal muscle, VAT, and SAT using cross-sectional CT images and investigated the association with the survival outcome of HCC patients treated with transcatheter intra-arterial therapies. It was revealed that a low SATI was an independent prognostic factor of poor OS in these patients, whereas no other body composition index affected the OS.

In cancer patients, adipose tissue lipolysis is augmented, whereas adipogenesis is weakened with cancer progression.[@b26-cmar-10-2231]--[@b30-cmar-10-2231] One of the major biological functions of white adipose tissue is energy storage, and it can protect cancer patients against increased energy exhaustion induced by the cachectic state.[@b31-cmar-10-2231]--[@b33-cmar-10-2231] In previous studies, SAT has been reported to be beneficial for lipid and glucose metabolism.[@b34-cmar-10-2231],[@b35-cmar-10-2231] Thus, these functions of SAT may contribute to the improvement of outcomes of patients with advanced HCC in this study.

Whether VAT accumulation is beneficial or harmful for the survival of HCC patients is currently controversial.[@b14-cmar-10-2231]--[@b17-cmar-10-2231] In contrast, a high VSR was revealed as an adverse prognostic factor for various malignancies, including HCC, in previous studies.[@b12-cmar-10-2231],[@b36-cmar-10-2231]--[@b38-cmar-10-2231] Contrary to the favorable effects of SAT, the detrimental effects of VAT have frequently been observed in cancer patients. Although VAT is also a component of white adipose tissues, it has functions distinct from SAT.[@b34-cmar-10-2231] VAT is a metabolically active endocrine organ, and its excess accumulation induces the alteration of expression levels of various adipokines, such as interleukin-6, tumor necrosis factor, and leptin, leading to carcinogenesis and tumor progression.[@b39-cmar-10-2231]--[@b41-cmar-10-2231] Furthermore, many studies have demonstrated that low skeletal muscle volume was also associated with poor clinical outcomes in HCC patients.[@b11-cmar-10-2231],[@b12-cmar-10-2231],[@b42-cmar-10-2231]--[@b46-cmar-10-2231]

Contrary to the significantly detrimental impacts of high VAT volume, high VSR, and low skeletal muscle volume reported previously, other than the SATI, the body composition indexes examined in this study were not significant prognosticators. We have considered that this discrepancy may be attributed to the more advanced tumor stages and less curative treatment undergone in most of our patients compared to subjects in previous studies, because, in general, tumor progression and treatment methods affect prognosis more profoundly than body composition changes in cancer patients.

To our knowledge, this is the first study that demonstrated the association between high SAT volume and improved survival outcomes of HCC patients treated with transcatheter intra-arterial therapies. The results of our study are consistent with those of previous studies on subjects with prostate cancer and multiple myeloma.[@b47-cmar-10-2231],[@b48-cmar-10-2231] The study that investigated multiple myeloma additionally showed that fluorodeoxyglucose (FDG) uptake as assessed by positron emission tomography CT (PET/CT) was significantly increased in patients with lower SAT volumes.[@b48-cmar-10-2231] This finding suggests that a more active tumor metabolism indicated by a higher FDG uptake may lead to hypercatabolism, which is responsible for a decrease in SAT volume. Although we were unable to assess FDG uptake because PET/CT is not performed as the routine workup for HCC, a similar mechanism may also be at work in our patients.

Several limitations of this study should be acknowledged. First, this was a single-institution study with a relatively small number of patients which was not sufficient to determine optimal cutoff values of the SATI to predict the outcomes of HCC patients. Besides, there were differences in sex and etiology between low- and high-SATI groups which may become confounding factors of the prognosis. Further study including a larger number of patients is needed to confirm our results. Second, the design of this study was retrospective, and we were unable to reveal the mechanism underlying the relationship between lower SAT volume and worse survival. A comprehensive investigation, including a biological analysis of SAT in patients with HCC, is required.

Conclusion
==========

This study found that high SAT volume is associated with better survival outcomes in HCC patients treated with transcatheter intra-arterial therapies. Further investigation to elucidate the mechanisms regulating SAT volume in cancer patients may lead to an improvement in clinical outcomes through early therapeutic interventions.

We would like to express our deep sorrow over Dr Satoshi Yamagiwa's passing, and sincere gratitude for his great contribution to this study.
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###### 

Baseline demographic and clinical characteristics

  Variable                                     Total (n=100)         Men (n=69)            Women (n=31)          *p*-value
  -------------------------------------------- --------------------- --------------------- --------------------- -----------
  Observation period (days), median \[IQR\]    746 \[466--1455\]     673 \[460--1473\]     826 \[563--1456\]     0.348
  Age (years), median \[IQR\]                  71 \[60--77\]         66 \[59--74\]         75 \[73--80\]         0.001
  BMI (kg/m^2^), median \[IQR\]                23.6 \[21.4--26.4\]   24.0\[22.0--26.4\]    22.7 \[20.8--26.7\]   0.206
  SMI (cm^2^/m^2^), median \[IQR\]             45.2 \[40.0--49.5\]   47.2 \[44.5--53.3\]   39.0 \[35.3--42.0\]   \<0.001
  VATI (cm^2^/m^2^), median \[IQR\]            42.2 \[23.9--58.6\]   47.8 \[29.8--58.5\]   30.3 \[15.4--60.6\]   0.126
  SATI (cm^2^/m^2^), median \[IQR\]            41.3 \[25.5--55.6\]   37.0 \[24.4--49.8\]   46.6 \[30.3--62.3\]   0.059
  VSR, median \[IQR\]                          0.97 \[0.69--1.28\]   1.07 \[0.83--1.78\]   0.75 \[0.45--0.93\]   \<0.001
  Etiology (HBV/HCV/NBNC), n                   11/49/40              11/28/30              0/21/10               0.012
  ALT (U/L), median \[IQR\]                    37 \[23--59\]         42 \[25--69\]         27 \[21--41\]         0.016
  Total bilirubin (mg/dL), median \[IQR\]      1.0 \[0.7--1.4\]      1.0 \[0.7--1.5\]      0.9 \[0.7--1.2\]      0.348
  Albumin (g/dL), median \[IQR\]               3.7 \[3.2--4.0\]      3.7 \[3.2--4.1\]      3.7 \[3.2--4.0\]      0.794
  Platelet count (×10^4^/µL), median \[IQR\]   12.2 \[7.4--17.3\]    12.2 \[7.4--18.1\]    12.0 \[7.4--15.9\]    0.835
  Child--Pugh classification (A/B), n          72/28                 47/22                 25/6                  0.235
  AFP (ng/mL), median \[IQR\]                  21.4 \[7.0--313.8\]   14.0 \[7.0--224.5\]   29.8 \[7.0--808.0\]   0.461
  TNM stage (I/II vs. III/IV), n               11/30 vs. 37/22       8/18 vs. 26/17        3/12 vs. 11/5         0.381
  Maximal tumor size (mm), median \[IQR\]      32 \[20--65\]         36 \[20--72\]         26 \[21--51\]         0.304
  Number of lesions (solitary/multiple), n     30/70                 19/50                 11/20                 0.482
  Treatment modality (TACE/TAI/TACE+TAI)       26/21/53              16/15/38              10/6/15               0.633
  mRECIST (CR/PR/SD vs. PD), n                 19/17/8 vs. 56        13/10/7 vs. 39        6/7/1 vs. 17          1.000
  BCAA supplementation (yes/no)                66/34                 46/23                 20/11                 0.824

**Abbreviations:** IQR, interquartile range; BMI, body mass index; SMI, skeletal muscle index; VATI, visceral adipose tissue index; SATI, subcutaneous adipose tissue index; VSR, visceral to subcutaneous adipose tissue area ratio; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, none of HBV or HCV; ALT, alanine transaminase; AFP, alpha-fetoprotein; TNM, tumor node metastasis; TACE, transcatheter arterial chemoembolization; TAI, transcatheter arterial infusion chemotherapy; mRECIST, Modified Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; BCAA, branched chain amino acids.

###### 

Spearman's correlation analysis among body composition indexes

               Men (n=69)   Women (n=31)                                                                         
  ------------ ------------ ---------------- --------------- ------------ ------------ ------------ ------------ ------------
  BMI          *r*=0.670    *r*=0.555        *r*=0.758 *r*   =−0.019      *r*=0.310    *r*=0.840    *r*=0.867    *r*=0.333
  *p*\<0.001   *p*\<0.001   *p*\<0.001 *p*   =0.875          *p*=0.090    *p*\<0.001   *p*\<0.001   *p*=0.067    
  SMI          --           *r*=0.201        *r*=0.456       *r*=−0.135   --           *r*=0.252    *r*=0.379    *r*=−0.061
               *p*=0.098    *p*\<0.001       *p*=0.270                    *p*=0.171    *p*=0.036    *p*=0.743    
  VATI         --           --               *r*=0.553       *r*=0.584    --           --           *r*=0.806    *r*=0.655
                            *p*\<0.001       *p*\<0.001                                *p*\<0.001   *p*\<0.001   
  SATI         --           --               --              *r*=−0.270   --           --           --           *r*=0.136
                                             *p*=0.025                                              *p*=0.465    

**Note:** "--" means omission of duplicated analysis.

**Abbreviations:** BMI, body mass index; SMI, skeletal muscle index; VATI, visceral adipose tissue index; SATI, subcutaneous adipose tissue index; VSR, visceral to subcutaneous adipose tissue area ratio.

###### 

Sex-specific cutoff values of body composition indexes

  Variable                   Cutoff value   Low, n   High, n
  ------------------- ------ -------------- -------- ---------
  VATI (cm^2^/m^2^)   Men    44.0           32       37
  Women               35.0   17             14       
  SATI (cm^2^/m^2^)   Men    40.0           38       31
  Women               30.0   7              24       
  VSR                 Men    1.08           35       34
  Women               0.86   20             11       

**Abbreviations:** VATI, visceral adipose tissue index; SATI, subcutaneous adipose tissue index; VSR, visceral to subcutaneous adipose tissue area ratio.

###### 

Univariate and multivariate analysis of clinical characteristics for overall survival using the Cox proportional hazards model

  Variable                                       Univariate analysis    Multivariate analysis                          
  ---------------------------------------------- ---------------------- ----------------------- ---------------------- ---------
  Age (years), \<70 vs. ≥70                      1.420 (0.868--2.323)   0.162                                          
  Sex, men vs. women                             1.327 (0.773--2.278)   0.305                                          
  BMI (kg/m^2^), \<25.0 vs. ≥25.0                1.498 (0.889--2.525)   0.129                                          
  SMI, low SMI vs. high SMI                      1.115 (0.640--1.943)   0.701                                          
  VATI, low VATI vs. high VATI                   1.153 (0.708--1.880)   0.567                                          
  SATI, low SATI vs. high SATI                   1.863 (1.135--3.057)   0.014                   2.065 (1.187--3.593)   0.010
  VSR, low VSR vs. high VSR                      0.631 (0.384--1.037)   0.069                                          
  ALT (U/L), \<30 vs. ≥30                        0.935 (0.571--1.530)   0.788                                          
  Total bilirubin (mg/dL), \<1.5 vs. ≥1.5        0.651 (0.374--1.133)   0.129                                          
  Albumin (g/dL), \<3.5 vs. ≥3.5                 1.749 (1.037--2.951)   0.036                   2.007 (1.037--3.886)   0.039
  Platelet count (×10^4^/µL), \<10.0 vs. ≥10.0   1.030 (0.627--1.693)   0.907                                          
  Child--Pugh classification, A vs. B            0.543 (0.316--0.933)   0.027                   0.630 (0.321--1.237)   0.180
  AFP (ng/mL), \<20 vs. ≥20                      0.375 (0.226--0.621)   \<0.001                 0.311 (0.179--0.540)   \<0.001
  TNM stage, I/II vs. III/IV                     0.558 (0.335--0.927)   0.024                   0.707 (0.381--1.313)   0.273
  Maximal tumor size, mm, \<30 vs. ≥30           0.464 (0.281--0.764)   0.003                   0.711 (0.377--1.343)   0.293
  Number of tumor, solitary vs. multiple         0.737 (0.427--1.272)   0.273                                          
  mRECIST assessment, CR+PR+SD vs. PD            0.379 (0.220--0.655)   \<0.001                 0.392 (0.221--0.696)   0.001
  BCAA supplementation, yes vs. no               1.421 (0.807--2.501)   0.224                                          

**Abbreviations:** BMI, body mass index; SMI, skeletal muscle index; VATI, visceral adipose tissue index; SATI, subcutaneous adipose tissue index; VSR, visceral to subcutaneous adipose tissue area ratio; ALT, alanine transaminase; AFP, alpha-fetoprotein; TNM, tumor node metastasis; mRECIST, Modified Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; BCAA, branched chain amino acids.

###### 

Comparison of demographic and clinical characteristics between low- and high-SATI groups

  Variable                                     Low SATI (n=45)       High SATI (n=55)      *p*-value
  -------------------------------------------- --------------------- --------------------- -----------
  Observation period (days), median \[IQR\]    611 \[450--1110\]     869 \[556--1563\]     0.089
  Age (years), median \[IQR\]                  71 \[62--78\]         70 \[59--76\]         0.822
  Sex (men/women), n                           38/7                  31/24                 0.004
  BMI and body composition indexes in men                                                  
   BMI (kg/m^2^), median \[IQR\]               22.3 \[20.4--23.6\]   26.2 \[24.9--28.3\]   \<0.001
   SMI (cm^2^/m^2^), median \[IQR\]            46.1 \[43.8--47.9\]   51.5 \[46.0--55.7\]   0.002
   VATI (cm^2^/m^2^), median \[IQR\]           32.8 \[19.7--51.0\]   56.0 \[47.8--70.1\]   \<0.001
   SATI (cm^2^/m^2^), median \[IQR\]           26.2 \[19.9--33.1\]   51.1 \[45.5--64.0\]   \<0.001
   VSR, median \[IQR\]                         1.14 \[0.92--2.04\]   1.00 \[0.73--1.29\]   0.103
  BMI and body composition indexes in women                                                
   BMI (kg/m^2^), median \[IQR\]               17.6 \[17.1--20.8\]   23.5 \[21.6--28.8\]   0.001
   SMI (cm^2^/m^2^), median \[IQR\]            33.7 \[33.6--36.0\]   40.2 \[35.9--42.5\]   0.014
   VATI (cm^2^/m^2^), median \[IQR\]           9.5 \[8.1--14.6\]     41.7 \[23.9--74.7\]   \<0.001
   SATI (cm^2^/m^2^), median \[IQR\]           16.6 \[12.1--20.6\]   53.9 \[43.9--82.3\]   \<0.001
   VSR, median \[IQR\]                         0.68 \[0.43--0.88\]   0.81 \[0.46--1.00\]   0.369
  Etiology (HBV/HCV/NBNC), n                   9/22/14               2/27/26               0.022
  ALT(U/L), median \[IQR\]                     41 \[23--79\]         32 \[23--50\]         0.216
  Total bilirubin (mg/dL), median \[IQR\]      1.0 \[0.7--1.5\]      0.9 \[0.8--1.3\]      0.911
  Albumin (g/dL), median \[IQR\]               3.7 \[3.2--4.1\]      3.7 \[3.2--4.0\]      0.821
  Platelet count (×10^4^/µL), median \[IQR\]   12.1 \[7.6--17.6\]    12.2 \[7.3--16.1\]    0.854
  Child--Pugh classification (A/B), n          29/16                 43/12                 0.179
  AFP (ng/mL), median \[IQR\]                  25.8 \[5.3--539.0\]   17.0 \[7.3--330.0\]   0.808
  TNM stage (I/II vs. III/IV), n               6/14 vs. 16/9         5/16 vs. 21/13        0.547
  Maximal tumor size (mm), median \[IQR\]      42 \[20--88\]         28 \[20--50\]         0.243
  Number of lesions (solitary/multiple), n     17/28                 13/42                 0.133
  Treatment modality (TACE/TAI/TACE+TAI)       10/9/26               16/12/27              0.657
  mRECIST (CR+PR+SD vs. PD), n                 21 vs. 24             23 vs. 32             0.688
  BCAA supplementation (yes/no)                30/15                 36/19                 1.000

**Abbreviations:** SATI, subcutaneous adipose tissue index; IQR, interquartile range; BMI, body mass index; SMI, skeletal muscle index; VATI, visceral adipose tissue index; VSR, visceral to subcutaneous adipose tissue area ratio; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, none of HBV or HCV was infected; ALT, alanine transaminase; AFP, alpha-fetoprotein; TNM, tumor node metastasis; TACE, transcatheter arterial chemoembolization; TAI, transcatheter arterial infusion chemotherapy; mRECIST, Modified Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; BCAA, branched chain amino acids.

[^1]: Dr Satoshi Yamagiwa passed away on May 4, 2018
